Rallybio Corporation earnings releases RLYB

Annual Quarterly

Rallybio Corporation last reported quarterly results on Nov 6, 2025, for Q3 FY2025 (the quarter ended Sep 30, 2025): revenue of $212,000 (-29.1% year over year) and diluted EPS of $2.84. It usually reports 37–72 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 37–72 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
Nov 6, 2025 37 days after quarter end	Q3 FY2025 ended Sep 30, 2025	0 -29.1%	16 +239.7%	2.84 +1192.3%
Aug 7, 2025 38 days after quarter end	Q2 FY2025 ended Jun 30, 2025	0 -29.1%	-10 +40.2%	-0.22 +40.5%
May 8, 2025 38 days after quarter end	Q1 FY2025 ended Mar 31, 2025	0	-9 +50.4%	-1.69 -259.6%
Mar 13, 2025 72 days after quarter end	Q4 FY2024 ended Dec 31, 2024	0	-11 +45.4%	0.10 +120.8%
Nov 7, 2024 38 days after quarter end	— ended Sep 30, 2024	—	—	—
Aug 8, 2024 39 days after quarter end	— ended Jun 30, 2024	—	—	—
May 9, 2024 39 days after quarter end	— ended Mar 31, 2024	—	—	—
Feb 6, 2024 37 days after quarter end	— ended Dec 31, 2023	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: RLYB (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: New Haven, CT
SEC filer status: , Emerging growth company
SEC CIK: 1739410
Former names: Rallybio Holdings, LLC (until Jun 7, 2021)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.